Deep Dive Into Exact Sciences Stock: Analyst Perspectives (8 Ratings)

Exact Sciences EXAS has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $65.0, a high estimate of $73.00, and a low estimate of $52.00. Highlighting a 7.67% decrease, the current average has fallen from the previous average price target of $70.40.

Exploring Analyst Ratings: An In-Depth Overview

The standing of Exact Sciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

| Analyst | Analyst Firm | Action Taken | Rating |Current Price Target| Prior Price Target | |--------------------|--------------------|---------------|-----------------|--------------------|--------------------| |Anthony Petrone |Mizuho |Announces |Outperform | $60.00|- | |Gerard Cassidy |RBC Capital |Announces |Sector Perform | $52.00|- | |David Westenberg |Piper Sandler |Lowers |Overweight | $70.00|$75.00 | |Sung Ji Nam |Scotiabank |Raises |Sector Outperform| $73.00|$70.00 | |Derik De Bruin |B of A Securities |Lowers |Buy | $65.00|$72.00 | |Luke Sergott |Barclays |Lowers |Overweight | $65.00|$70.00 | |Luke Sergott |Barclays |Announces |Overweight | $70.00|- | |Bruce Jackson |Benchmark |Maintains |Buy | $65.00|$65.00 |

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exact Sciences. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Exact Sciences compared to the broader market.
• Price Targets: Delving into movements, analysts provide estimates for the future value of Exact Sciences's stock. This analysis reveals shifts in analysts' expectations over time.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Exact Sciences's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Exact Sciences analyst ratings.

All You Need to Know About Exact Sciences

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Understanding the Numbers: Exact Sciences's Finances

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Growth: Exact Sciences's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 10.29%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Exact Sciences's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -121.19%, the company may face hurdles in effective cost management.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -30.81%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): Exact Sciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -13.64%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Exact Sciences's debt-to-equity ratio is below the industry average at 1.15, reflecting a lower dependency on debt financing and a more conservative financial approach.

Analyst Ratings: Simplified

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.